Source: International Congress 2018 – Lung cancer: from the bench to the bedside
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
I. Giopanou, D. Simoglou (dsimoglou@gmail.com / Laboratory for Molecular Respiratory Carcinogenesis, D. of Physiology, F. of Medicine, U. of Patras,Patras), M. Lianou (marina_lianou@hotmail.com / Laboratory for Molecular Respiratory Carcinogenesis, D. of Physiology, F. of Medicine, U. of Patras,Patras), G. T Stathopoulos (gstathop@upatras.gr / Laboratory for Molecular Respiratory Carcinogenesis, D. of Physiology, F. of Medicine, U. of Patras,Patras). LSC - 2018 - Nuclear factor ??-signalling drives Malignant Pleural Mesothelioma. 2840

Member's Comments

No comment yet.

Related content which might interest you: Role of fibulin-3 in the diagnosis of malignant mesothelioma Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma Year: 2014 Malignant Mesothelioma: Place for thoracoscopy Source: School Course 2014 - Thoracoscopy and Pleural Techniques Year: 2014 Malignant Mesothelioma: Place for thoracoscopy Source: School Course 2014 - Thoracoscopy and Pleural Techniques Year: 2014 Predictive value of pro-inflammatory cytokine and pro-angiogenic factor in differentiating malignant from benign exudative effusion Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Management of recurrent Malignant Pleural Effusion: what is the best method? Source: ERS Course 2015 Year: 2015 Management of recurrent Malignant Pleural Effusion: what is the best method? Source: School Course 2014 - Thoracoscopy and Pleural Techniques Year: 2014 Malignant mesothelioma vs metastatic carcinoma of pleura: Do pathology and radiology agree? Source: Annual Congress 2013 –Morphologic imaging Year: 2013 Malignant pleural mesothelioma: Facts & survival rate Source: Annual Congress 2011 - Pleural and mediastinal malignancies: management and rare clinical cases Year: 2011 Malignant pleural mesothelioma: Current status and future projections in Turkey Source: International Congress 2015 – Mediastinal tumors, malignant pleural mesothelioma and other rare tumors Year: 2015 Activated KRAS signaling triggers malignant pleural effusion Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management Year: 2015 Malignant Mesothelioma: place for thoracoscopy Source: ERS Skills Course 2016 Year: 2016 Pleural mesothelioma: Our experience in 132 cases Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma Year: 2014 Malignant pleural mesothelioma: A retrospective analysis of 32 cases Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Current practice: Pleural fluid sampling and analysis - how well are we doing? Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013 LATE-BREAKING ABSTRACT: Host-environmental IL-1ß drives mutant KRAS-IKKa addiction in malignant pleural effusion Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management Year: 2015 Hemorrhagic malignant pleural effusion: Diagnosis, survival rate, and response to talc pleurodesis Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Volume quantification of malignant pleural mesothelioma Source: International Congress 2015 – Malignant pleural effusions and mesothelioma Year: 2015 LSC - 2017 - Proteasomal Activator 200 (PA200) Regulates Cellular Proliferation: A Putative Role For IPF And Lung Cancer Pathogenesis Source: International Congress 2017 – New insights into pathogenesis of lung disease  Year: 2017